Updated: Oct. 17, 2025

• Placement of Seven Specific Fentanyl Related Substances in Schedule I for Controlled Substances 10/15/2025
• Placement of Ethylphenidate in Schedule I for Controlled Substances 11/21/2024
• Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule for Controlled Substances 8/28/2024
• Placement of MDMB-4en-PINACA, 4F-MDMB-BUTICA, ADB- 4en-PINACA, CUMYL-PEGACLONE, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I for Controlled Substances 1/4/2024
• Placement of Nine Specific Fentanyl-Related Substances in Schedule I for Controlled Substances 1/4/2024
• Placement of Zuranolone into Schedule IV for Controlled Substances 11//9/2023
• Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I for Controlled Substances 8/10/2023
• Removal of Fenfluramine from Schedule IV for Controlled Substances 1/5/2023
• Placement of Methiopropamine in Schedule I for Controlled Substances 1/5/2023
• Placement of Mesocarb in Schedule I for Controlled Substances 12/08/2022
• Placement of Substances in Schedule III for Controlled Substances 12/08/2022
• Placement of Amineptine in Schedule I for Controlled Substances 12/08/2022
• Placement of Zipeprol in Schedule I for Controlled Substances 12/08/2022
• Placement of Ganaxolone into Schedule V for Controlled Substances 06/29/2022
• Placement of Methoxetamine in Schedule I for Controlled Substances 06/29/2022
• Placement of Butonitazene, Etodesnitazene, Flunitazene, Metodesnitazene, Metonitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I for Controlled Substances 05/05/2022
• Placement of 4,4′- DMAR in Schedule I for Controlled Substances 09/09/2021
• Placement of 4F-MDMB-BINACA in Schedule I for Controlled Substances 07/15/2021
• Placement of para-Methoxymethamphetamine in Schedule I for Controlled Substances 07/15/2021
• Placement of 10 Specific Fentanyl-Related Substances in Schedule I for Controlled Substances 05/13/2021
• Placement of Four Specific Fentanyl-Related Substances in Schedule I for Controlled Substances 05/13/2021
• Placement of Serdexmethylphenidate in Schedule IV for Controlled Substances 05/13/2021
• Placement of Oliceridine into Schedule II for Controlled Substances 11/12/2020
• Placement of Remimazolam into Schedule IV for Controlled Substances 10/08/2020
• Placement of Crotonyl Fentanyl into Schedule I for Controlled Substances 10/08/2020
• Removal of FDA Approved Drugs That Contain Cannabidiol (CBD) Derived From Cannabis And No More Than 0.1 Percent (w/w) Residual Tetrahydrocannabinols From Schedule V For Controlled Substances 09/10/2020
• Placement of Isotonitazene into Schedule I for Controlled Substances 09/10/2020
• Placement of Norfentanyl into Schedule II for Controlled Substances 05/07/2020
• Placement of Cenobamate into Schedule V for Controlled Substances 04/09/2020
• Placement of Lemborexant into Schedule IV for Controlled Substances 04/09/2020
• Placement of Lasmiditan into Schedule V for Controlled Substances 02/13/2020
• Placement of N-ethylhexedrone, α-PHP, 4-MEAP, MPHP, PV8, and 4-Chloro-α-PVP into Schedule I for Controlled Substances 8/8/2019
• Placement of Solriamfetol into Schedule IV for Controlled Substances 7/11/2019
• Placement of Brexanolone into Schedule IV for Controlled Substances 7/11/2019
• Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 into Schedule I for Controlled Substances 5/09/2019
• Placement of FDA-Approved Cannabidiol Drugs containing no more than 0.1% Tertrahydrocannabinols in Schedule V for Controlled Substances 10/12/2018
• Placement of N-Ethylpentylone into Schedule I for Controlled Substances 10/01/2018
• Placement of NM2201, SF-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA, and 5F-CUMYL-P7AICA into Schedule I for Controlled Substances 7/12/2018
• Placement of Fentanyl Related Substances into Schedule I for Controlled Substances 2/08/2018
• Placement of valeryl fentanyl, para-fluorobutyryl fentanyl, para-methoxybutyryl fentanyl, parachloroisobutyryl fentanyl, cyclopentyl fentanyl, and ocfentanil into Schedule I for Controlled Substances 2/08/2018
• Placement of Cyclopropyl Fentanyl into Schedule I of the S.C. Controlled Substances Act 1/30/2018
• Placement of MT-45 into Schedule I of the S.C. Controlled Substances Act 1/04/2018
• Placement of FUB—AMB into Schedule I of the S.C. Controlled Substances Act 11/09/2017
• Placement of Ortho-Fluorofentanyl, Tetrahydrofuranyl Fentanyl, and Methoxyacetyl Fentanyl into Schedule I of the S.C. Controlled Substances Act 11/09/2017
• Placement of Acryl Fentanyl into Schedule I of the S.C. Controlled Substances Act 08/10/2017
• Placement of 4-Fluoroisobutyryl Fentanyl into Schedule I of S.C. Controlled Substances Act 05/11/2017
• Placement of Dronabinol (in oral solution) in Schedule II 04/05/2017.
• Placement of the synthetic opioid, N-(l-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide (furanyl fentanyl), into Schedule I of the S.C. Controlled Substances Act 12/08/2016
• Placement of the synthetic opioid, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U-47700), into schedule I for Controlled Substances 11/10/2016
• Placement of Thiafentanil into Schedule II for Controlled Substances (9/8/2016)
• Placement of Brivaracetam into Schedule V for Controlled Substances (6/9/2016)
• Placement of AH-7921 into Schedule I for Controlled Substances (5/12/2016)
• Temporary Placement of Butyryl fentanyl and Beta-hydroxythiofentanyl into Schedule I of the S.C. Controlled Substances Act (5/12/2016)
• Placement of Synthetic Cathinones in Schedule I for Controlled Substances (3/10/2016)
• Corrected Classification for Schedule I Controlled Substances (12/10/2015)
• Placement of Eluxadoline into Schedule IV for Controlled Substances
• Placement of Acetyl Fentanyl into Schedule I of the S.C. Controlled Substances Act
• Removal of [123I]ioflupane from Schedule II of the S.C. Controlled Substances Act
• DEA Scheduling of Three Synthetic Cannabinoids
• Exclusion of Naloxegol from the S.C. Controlled Substances Act
• List of Substances for Inclusion in the S.C. ControlledSubstances Act (Updated 12/11/2014)
• Signed Board Designation - Update to the Schedules of Controlled Substances
• Placement of Suvorexant into Schedule IV for Controlled Substances
• Rescheduling of Hydrocodone Combination Products from Schedule III to Schedule II for Controlled Substances 9-11-2014
• Placement of tramadol (Ultram) 07-10-2014
• Placement of Alfaxalone 03-13-2014
• Placement of Bath Salts, K2 and Spice 10-24-2011
• Placement of Carisoprodol (Soma) 02-09-2012
• Placement of Four Synthetic Cannabinoids 02-27-2014
• Placement of lorcaserin 06-24-2013
• Placement of Synthetic Cannabinoids (Marijuana) 05-19-2013
• Placement of Three Synthetic Phenethylamines 12-12-2013
• Placement of N-Ethylpentylone into Schedule I for Controlled Substances 10/01/2018
• Placement of NM2201, SF-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA, and 5F-CUMYL-P7AICA into Schedule I for Controlled Substances 7/12/2018
• Placement of Fentanyl Related Substances into Schedule I for Controlled Substances 2/08/2018
• Placement of valeryl fentanyl, para-fluorobutyryl fentanyl, para-methoxybutyryl fentanyl, parachloroisobutyryl fentanyl, cyclopentyl fentanyl, and ocfentanil into Schedule I for Controlled Substances 2/08/2018
• Placement of Cyclopropyl Fentanyl into Schedule I of the S.C. Controlled Substances Act 1/30/2018
• Placement of MT-45 into Schedule I of the S.C. Controlled Substances Act 1/04/2018
• Placement of FUB—AMB into Schedule I of the S.C. Controlled Substances Act 11/09/2017
• Placement of Ortho-Fluorofentanyl, Tetrahydrofuranyl Fentanyl, and Methoxyacetyl Fentanyl into Schedule I of the S.C. Controlled Substances Act 11/09/2017
• Placement of Acryl Fentanyl into Schedule I of the S.C. Controlled Substances Act 08/10/2017
• Placement of 4-Fluoroisobutyryl Fentanyl into Schedule I of S.C. Controlled Substances Act 05/11/2017
• Placement of Dronabinol (in oral solution) in Schedule II 04/05/2017.
• Placement of the synthetic opioid, N-(l-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide (furanyl fentanyl), into Schedule I of the S.C. Controlled Substances Act 12/08/2016
• Placement of the synthetic opioid, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U-47700), into schedule I for Controlled Substances 11/10/2016
• Placement of Thiafentanil into Schedule II for Controlled Substances (9/8/2016)
• Placement of Brivaracetam into Schedule V for Controlled Substances (6/9/2016)
• Placement of AH-7921 into Schedule I for Controlled Substances (5/12/2016)
• Temporary Placement of Butyryl fentanyl and Beta-hydroxythiofentanyl into Schedule I of the S.C. Controlled Substances Act (5/12/2016)
• Placement of Synthetic Cathinones in Schedule I for Controlled Substances (3/10/2016)
• Corrected Classification for Schedule I Controlled Substances (12/10/2015)
• Placement of Eluxadoline into Schedule IV for Controlled Substances
• Placement of Acetyl Fentanyl into Schedule I of the S.C. Controlled Substances Act
• Removal of [123I]ioflupane from Schedule II of the S.C. Controlled Substances Act
• DEA Scheduling of Three Synthetic Cannabinoids
• Exclusion of Naloxegol from the S.C. Controlled Substances Act
• List of Substances for Inclusion in the S.C. ControlledSubstances Act (Updated 12/11/2014)
• Signed Board Designation - Update to the Schedules of Controlled Substances
• Placement of Suvorexant into Schedule IV for Controlled Substances
• Rescheduling of Hydrocodone Combination Products from Schedule III to Schedule II for Controlled Substances 9-11-2014
• Placement of tramadol (Ultram) 07-10-2014
• Placement of Alfaxalone 03-13-2014
• Placement of Bath Salts, K2 and Spice 10-24-2011
• Placement of Carisoprodol (Soma) 02-09-2012
• Placement of Four Synthetic Cannabinoids 02-27-2014
• Placement of lorcaserin 06-24-2013
• Placement of Synthetic Cannabinoids (Marijuana) 05-19-2013
• Placement of Three Synthetic Phenethylamines 12-12-2013